Last reviewed · How we verify
THC:CBD 1:1
At a glance
| Generic name | THC:CBD 1:1 |
|---|---|
| Also known as | Cannabis |
| Sponsor | Wayne State University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- High blood pressure
- Acid reflux
Key clinical trials
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Medical Cannabis During Chemoradiation for Head and Neck Cancer
- Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery (PHASE1)
- Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors (PHASE2)
- Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans (PHASE2)
- Repeated Cannabis Administration on Experimental Pain and Abuse Liability (PHASE2)
- CANnabinoids in Pediatric ONCology (PHASE1, PHASE2)
- Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THC:CBD 1:1 CI brief — competitive landscape report
- THC:CBD 1:1 updates RSS · CI watch RSS
- Wayne State University portfolio CI